Study Overview: Clinical Trial

The safety and efficacy of VOXZOGO® (vosoritide) were evaluated in patients with achondroplasia aged 5 to 15 years1,2

Clinical study overview1,2

*One patient discontinued due to pain, and one discontinued due to anxiety with injections.


  1. VOXZOGO® Product Information, 2022
  2. Savarirayan R, Tofts L, Irving M, et al. Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial. Lancet. 2020;396:684-692.